July 5, 2018
May was a busy month for Action’s International Client Hub team as they jetted to Vienna to support Boehringer Ingelheim, one of the pharmaceutical industry’s top 20 companies, in their CEE Respiratory Expert Forum. The event – a two-day thought-leadership forum running under the headline ‘State of the art in preventing and treating COPD exacerbations’ – brought leading experts from the respiratory field together, to discuss new insights in the treatment of Chronic Obstructive Pulmonary Disease (COPD), and the results of a study about Spiolto®, Boehringer Ingelheim’s new advance in COPD maintenance therapy, which is built on the active ingredient in Spiriva®, the world´s most prescribed COPD treatment with over 50 million patient years’ experience1.
Action took the lead on media engagement and activities, running a regional media workshop at the event with expert speakers from the UK and Austria talking about the latest developments in the respiratory landscape, attended by journalists from across the CEE and wider region. In addition to coordinating the attendance of medical journalists, the team also worked with the client on external messaging around the event, developed materials and press kit collateral, and managed an interactive Q&A session as well as one-on-one onsite interviews with various spokespeople.
With 14 medical journalists from 8 countries in attendance, and over 10 interviews organised and managed by Action, the event was a great success, with positive feedback shared by both the speakers and journalists.
Action’s International Client Hub team has been leading PR activities for Boehringer Ingelheim’s prescription medicines portfolio in 16 countries across the CEE region for more than 10 years.
- Data on File, Boehringer Ingelheim, Ingelheim, Germany 2016